Expanding the Pool in Orthotopic Heart Transplantation: The Use of Hepatitis C Positive Donor Hearts in Hepatitis C Negative Recipients
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 10 Oct 2019 Planned End Date changed from 1 Jul 2019 to 1 Jul 2023.
- 10 Oct 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2023.
- 25 Mar 2019 planned patient numbers, trial design, trial focus, outcome measures, patient eligibility has been amended.